Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | FAAH | O00519 | 9/20 | 0.42 |
| ▸ | CES1 | P23141 | 5/20 | 0.42 |
| ▸ | CES2 | O00748 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | CETP | P11597 | 1/20 | 0.40 |
| ▸ | RORA | P35398 | 1/20 | 0.40 |
| ▸ | RORC | P51449 | 1/20 | 0.40 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19407452 | 1.00 | MEN1 (0.49) | MEN1KMT2AHSP90AA1GAAFAAH | |
| SCHEMBL19386087 | 0.98 | MEN1 (0.50) | MEN1KMT2AHSP90AA1GAAFAAH | |
| SCHEMBL21459121 | 0.94 | MEN1 (0.51) | MEN1KMT2AGAACYP1A2CETP | |
| SCHEMBL19407450 | 0.87 | GAA (0.47) | MEN1KMT2AGAAMAPK1 | |
| SCHEMBL21458994 | 0.85 | MEN1 (0.70) | MEN1KMT2AGAARORC | |
| SCHEMBL19407510 | 0.85 | MEN1 (0.70) | MEN1KMT2AGAARORC | |
| SCHEMBL18328441 | 0.81 | KMT2A (0.47) | MEN1KMT2AHSP90AA1GAAFAAH | |
| SCHEMBL19385974 | 0.81 | MEN1 (0.48) | MEN1KMT2AGAA | |
| SCHEMBL19407350 | 0.80 | FAAH (0.33) | MEN1KMT2AHSP90AA1FAAHCES1 | |
| SCHEMBL26623127 | 0.80 | KMT2A (0.49) | MEN1KMT2AHSP90AA1GAAFAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109563045-B | Pd (II) -catalysed enantioselective beta-methylene C (sp) 3 ) -H bond activation | 斯克里普斯研究学院 | 2022-08-23 | — | — | CN | disclosed |
| US-11186563-B2 | Pd(II)-catalyzed enantioselective β-methylene C(sp3)—H bond activation | THE SCRIPPS RESEARCH INSTITUTE (US) | 2021-11-30 | — | — | US | disclosed |
| US-11186563-B2 | Pd(II)-catalyzed enantioselective β-methylene C(sp3)—H bond activation | THE SCRIPPS RESEARCH INSTITUTE (US) | 2021-11-30 | — | — | US | disclosed |
| US-20190315710-A1 | Pd(II)-catalyzed Enantioselective Beta-Methylene C(sp3)–H Bond Activation | THE SCRIPPS RESEARCH INSTITUTE | 2019-10-17 | — | — | US | disclosed |
| US-20190315710-A1 | Pd(II)-catalyzed Enantioselective Beta-Methylene C(sp3)–H Bond Activation | THE SCRIPPS RESEARCH INSTITUTE | 2019-10-17 | — | — | US | disclosed |
| CN-109563045-A | Pd (II) -catalyzed enantioselectivity β -methylene C (sp)3) -H bond activation | 斯克里普斯研究学院 | 2019-04-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190315710-A1 | Pd(II)-catalyzed Enantioselective Beta-Methylene C(sp3)–H Bond Activation | POLQ, AP3D1, AP3S1 | MEN1 3613/4885KMT2A 787/4885HSP90AA1 4783/4885 |
| US-11186563-B2 | Pd(II)-catalyzed enantioselective β-methylene C(sp3)—H bond activation | POLQ, AP3D1, AP3S1 | MEN1 3604/4885KMT2A 666/4885HSP90AA1 4760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.